These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 16267618)

  • 1. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer.
    Abrial SC; Penault-Llorca F; Delva R; Bougnoux P; Leduc B; Mouret-Reynier MA; Mery-Mignard D; Bleuse JP; Dauplat J; Curé H; Chollet P
    Breast Cancer Res Treat; 2005 Dec; 94(3):255-63. PubMed ID: 16267618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer.
    Pierga JY; Mouret E; Diéras V; Laurence V; Beuzeboc P; Dorval T; Palangié T; Jouve M; Vincent-Salomon A; Scholl S; Extra JM; Asselain B; Pouillart P
    Br J Cancer; 2000 Dec; 83(11):1480-7. PubMed ID: 11076657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
    Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Cho N; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    Breast Cancer Res Treat; 2009 Jul; 116(1):153-60. PubMed ID: 18787948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy.
    Buchholz TA; Hill BS; Tucker SL; Frye DK; Kuerer HM; Buzdar AU; McNeese MD; Singletary SE; Ueno NT; Pusztai L; Valero V; Hortobagyi GN
    Cancer J; 2001; 7(5):413-20. PubMed ID: 11693900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.
    Guarneri V; Broglio K; Kau SW; Cristofanilli M; Buzdar AU; Valero V; Buchholz T; Meric F; Middleton L; Hortobagyi GN; Gonzalez-Angulo AM
    J Clin Oncol; 2006 Mar; 24(7):1037-44. PubMed ID: 16505422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
    Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
    Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
    Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA
    Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy.
    Amat S; Penault-Llorca F; Cure H; Le Bouedëc G; Achard JL; Van Praagh I; Feillel V; Mouret-Reynier MA; Dauplat J; Chollet P
    Int J Oncol; 2002 Apr; 20(4):791-6. PubMed ID: 11894126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients].
    Guan Y; Xu BH; Li Q; Zhang P; Zhao LM; Yuan P; Wang JY
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):77-81. PubMed ID: 18353207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic value of estrogen and progesterone receptors in the operable breast cancer: results of a uni- and multifactorial analysis].
    Chevallier B; Heintzman F; Asselain B; Dauce JP; Bastit P; Graic Y; Brunelle P; Basuyau JP; Comoz M
    Bull Cancer; 1988; 75(1):23-36. PubMed ID: 3359056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of axillary microresiduals after neoadjuvant chemotherapy in breast cancer patients with cytologically proven metastases.
    Sakakibara M; Nagashima T; Kadowaki M; Onai Y; Fujimori T; Yokomizo J; Suzuki H; Fushimi K; Nakatani Y; Miyazaki M
    Ann Surg Oncol; 2009 Sep; 16(9):2470-8. PubMed ID: 19588201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Percent positive axillary lymph node metastasis predicts survival in patients with non-metastatic breast cancer.
    Lale Atahan I; Yildiz F; Ozyigit G; Sari S; Gurkaynak M; Selek U; Hayran M
    Acta Oncol; 2008; 47(2):232-8. PubMed ID: 17924207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy.
    Tacca O; Penault-Llorca F; Abrial C; Mouret-Reynier MA; Raoelfils I; Durando X; Achard JL; Gimbergues P; Curé H; Chollet P
    Oncologist; 2007 Jun; 12(6):636-43. PubMed ID: 17602055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of residual breast disease and axillary node involvement for patients who had primary induction chemotherapy for advanced breast cancer.
    Escobar PF; Patrick RJ; Rybicki LA; Hicks D; Weng DE; Crowe JP
    Ann Surg Oncol; 2006 Jun; 13(6):783-7. PubMed ID: 16604475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer and neoadjuvant therapy: any predictive marker?
    Vyzula R; Dusek L; Zaloudík J; Demlová R; Klimes D; Selvekerová S
    Neoplasma; 2004; 51(6):471-80. PubMed ID: 15640958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stage-to-stage comparison of neoadjuvant chemotherapy versus adjuvant chemotherapy in pathological lymph node positive breast cancer patients.
    Lee NK; Shin KH; Park IH; Lee KS; Ro J; Jung SY; Lee S; Kim SW; Kim TH; Kim JY; Kang HS; Cho KH
    Jpn J Clin Oncol; 2012 Nov; 42(11):995-1001. PubMed ID: 22911001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome.
    Mazouni C; Peintinger F; Wan-Kau S; Andre F; Gonzalez-Angulo AM; Symmans WF; Meric-Bernstam F; Valero V; Hortobagyi GN; Pusztai L
    J Clin Oncol; 2007 Jul; 25(19):2650-5. PubMed ID: 17602071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.